Search | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Long term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival.

    ... due to intense intravascular hemolysis . Eculizumab , a monoclonal antibody against the complement protein ... in PNH. We evaluated 79 consecutive patients treated with eculizumab in Leeds between May 2002 and July 2010. Mortality and disease ...

    Research Article last updated 07/20/2018 - 5:14pm.

  2. Eculizumab in Pregnant Patients with Paroxysmal Nocturnal Hemoglobinuria

    ... BACKGROUND: Eculizumab , a humanized monoclonal antibody against complement ... of life and overall survival, but data on the use of eculizumab in women during pregnancy are scarce. METHODS: We ...

    Research Article last updated 07/20/2018 - 5:15pm.

  3. Chronic treatment of paroxysmal nocturnal hemoglobinuria patients with eculizumab: safety, efficacy, and unexpected laboratory phenomena

    ... The terminal complement inhibitor eculizumab has become the standard of treatment in patients with ... study, 19 PNH patients received chronic therapy with eculizumab with a median duration of 16 months (range 6-46 months). Parameters ...

    Research Article last updated 07/20/2018 - 5:14pm.

  4. Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab

    ... hemolysis , effectively controlled with eculizumab , a humanized monoclonal antibody that binds complement ... data, hemolysis biomarkers, complement assessment and free eculizumab circulating levels were systematically measured immediately prior ...

    Research Article last updated 07/20/2018 - 5:15pm.

  5. Predictors of Hemoglobin Response to Eculizumab Therapy in Paroxysmal Nocturnal Hemoglobinuria

    ... hemolytic anemia and bone marrow failure . Eculizumab has been shown to improve anemia, decrease intravascular ... retrospective, single-center study of patients treated with Eculizumab and categorized according to response criteria. Complete response ...

    Research Article last updated 07/20/2018 - 5:14pm.

  6. Polymorphism of the complement receptor 1 gene correlates with hematological response to eculizumab in patients with paroxysmal nocturnal hemoglobinuria

    ... Complement blockade by eculizumab is clinically effective in hemolytic Paroxysmal Nocturnal ... with hemolytic Paroxysmal Nocturnal Hemoglobinuria on eculizumab we tested the hypothesis that response may depend on genetic ...

    Research Article last updated 07/20/2018 - 5:15pm.

  7. Evaluation of hemostasis and endothelial function in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab.

    ... before and after five and 11 weeks of treatment with eculizumab . We examined markers of thrombin generation and reactional ... with no history of clinical thrombosis. Treatment with eculizumab was associated with significant decreases in plasma markers ...

    Research Article last updated 07/20/2018 - 5:14pm.

  8. Successful pregnancy outcome in paroxysmal nocturnal hemoglobinuria (PNH) following escalated eculizumab dosing to control breakthrough hemolysis

    ... syndrome and PNH. After two years of treatment with eculizumab , she became pregnant. She developed breakthrough hemolysis ... and pharmacodynamic studies demonstrated a subtherapeutic eculizumab level with absence of complement blockade. Escalation of her ...

    Research Article last updated 07/20/2018 - 5:15pm.

  9. Efficacy and safety of eculizumab in children and adolescents with paroxysmal nocturnal hemoglobinuria

    ... with reduced survival. The terminal complement inhibitor eculizumab is proven to be effective and safe in adults and approved by the ... and safety in seven children with PNH 11-17 years of age. Eculizumab was intravenously administered at 600 mg weekly for 4 weeks, ...

    Research Article last updated 07/20/2018 - 5:15pm.

  10. Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria.

    ... the safety and efficacy of the complement inhibitor eculizumab in altering its progression. Renal dysfunction or damage was ... rate [GFR] <or=60 ml/min/1.73 m(2); Stage 3, 4, or 5). Eculizumab treatment was safe and well-tolerated in patients with renal ...

    Research Article last updated 07/20/2018 - 5:14pm.